Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from FOXO Technologies ( (FOXO) ) is now available.
On July 31, 2025, FOXO Technologies announced that its subsidiary, Myrtle Recovery Centers, Inc., successfully renewed its operating license for its Oneida, TN location for another year. This renewal, following a successful inspection by the State of Tennessee’s Department of Mental Health and Substance Abuse Services, allows the facility to continue its operations at full capacity and manage a waiting list for future admissions. The company is considering strategic options for expansion, including opening a second location and potential acquisitions, to leverage Myrtle’s success.
Spark’s Take on FOXO Stock
According to Spark, TipRanks’ AI Analyst, FOXO is a Underperform.
FOXO Technologies receives a low overall stock score primarily due to significant financial challenges, including continuous net losses, high debt, and negative cash flows. The technical analysis also suggests bearish momentum. Although valuation metrics are poor, recent corporate actions, such as acquisitions and restructuring, provide some hope for future improvement. However, these are not sufficient to outweigh the current financial and operational challenges facing the company.
To see Spark’s full report on FOXO stock, click here.
More about FOXO Technologies
FOXO Technologies Inc. operates in the healthcare and biotechnology sectors, owning subsidiaries such as Myrtle Recovery Centers, Inc., which provides behavioral health services, and FOXO Labs, Inc., which focuses on biotechnology innovations. The company also owns Rennova Community Health, Inc., which operates a critical access hospital in Tennessee.
Average Trading Volume: 3,772,218
Technical Sentiment Signal: Sell
Current Market Cap: $2.23M
Find detailed analytics on FOXO stock on TipRanks’ Stock Analysis page.